Incidence of Sarcoma in Patients Undergoing Hysterectomy for Benign Indications: A Population-Based Study
Angioni, StefanoMember of the Collaboration Group
;
2019-01-01
Abstract
Minimally invasive hysterectomy may require the use of morcellation to remove the uterus. In the presence of unexpected sarcoma, morcellation risks disseminating malignant cells and worsening survival outcomes. As a consequence, in 2014 the US Food and Drug Administration (FDA) issued a black box warning against the use of power morcellator for the treatment of uterine fibroids. However, the proportion of unexpected sarcoma at the time of hysterectomy for presumed benign indication remains unclear.File | Size | Format | |
---|---|---|---|
Mutinu Am J Ob Gyn 2019.pdf Solo gestori archivio
Type: versione editoriale
Size 508.59 kB
Format Adobe PDF
|
508.59 kB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.